General Clinical Chemistry Analyzers and Accessories
Abcam AZ-20, 25MG
MW 412.5 Da. Potent and selective ATR kinase inhibitor (IC₅₀ = 5 nM in vitro; IC₅₀ = 50 nM in carcinoma cell lines). Selective versus mTOR (8-fold). Displayed selectivity versus a panel of 442 kinases.Inhibits LoVo colorectal adenocarcinoma tumor cell growth.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Vistusertib (AZD2014), 10MG
MW 462.5 Da, Purity >98%. Novel potent and selective mammalian rapamycin (mTOR) inhibitor (IC₅₀ = 2.8 nM). Highly selective against multiple PI3K isoforms. Also targets P-Akt (IC₅₀ = 80 nM) and pS6 (IC₅₀ = 200 nM). An oral inhibitor with potential anti-neoplastic activity.
The product is subject to the following: Abcam Restricted Use Statement
Abcam PF-573228, 50MG
MW 491.5 Da, Purity >=98%. Potent and selective FAK inhibitor (IC₅₀ = 4 nM versus recombunant catalytic fragent). Blocks FAK Tyr397phosphorylation in cultured cells (IC₅₀ = 30–100 nM). Shows 50 - 250-fold selectivity for FAK aginst a panel of 40 recombinant kinases. Inhibits chemotactic and haptotactic cell migration.
The product is subject to the following: Abcam Restricted Use Statement
Abcam CHIR-124, 5MG
MW 419.9 Da, Purity >98%. Novel and potent Chk1 inhibitor (IC₅₀ = 0.3 nM), 2,000-fold more potent than Chk2 (IC₅₀ = 0.7 μM). Also, potently targets other kinases such as FLT3 (IC₅₀ = 5.8 nM), PDGFR (IC₅₀ = 6.6 nM), GSK-3 (IC₅₀ = 23.3 nM) and Fyn (IC₅₀ = 98.8 nM) .
The product is subject to the following: Abcam Restricted Use Statement
Abcam Ponesimod, sphingosine-1-phophate receptor agonist, 25MG
MW 461 Da. Ponesimod is a potent agonist of sphingosine-1-phophate receptor. (S1P₁/EDG-1; IC₅₀s = 6, >10,000, 2,068, 1,956, and 142 nM for S1P₁-S1P₅, respectively, in a radioligand binding assay). Selectively activates S1P₁ in a GTPγS assay (EC₅₀s = 5.7, >10,000, 105, 1,108, and 59.1 nM, for S1P₁-S1P₅, respectively).
The product is subject to the following: Abcam Restricted Use Statement
Abcam TC 14012, Peptidomimetic C x CR4 antagonist, 1MG
MW 2066.4 Da, Purity >95%. TC 14012, Peptidomimetic CXCR4 antagonist. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam PF-04929113 (SN x -5422), 10MG
MW 521.5 Da, Purity >99%. Potent and selective Hsp90 inhibitor (IC₅₀ = 50 nM). A Her-2 degradation inducer (IC₅₀ = 37 nM).
The product is subject to the following: Abcam Restricted Use Statement
Abcam AZD1480, 10MG
MW 348.76 Da, Purity >98%. Novel, potent and selective small-molecule JAK2 inhibitor (IC₅₀ < 3 nM). It can effectively inhibit tumor angiogenesis and metastasis mediated by STAT3 in stromal cells as well as tumor cells. Also demonstrates >50-fold selectivity for JAK2 over JAK3.
The product is subject to the following: Abcam Restricted Use Statement
Abcam LCL161, 5MG
MW 500.6 Da, Purity >99%. Small molecule SMAC mimetic inhibitor of multiple IAP (Inhibitor of apoptosis) family proteins. (IC₅₀ = 10.23 μM). Inhibits cell proliferation and viability in two human hepatocellular carcinoma cells (Hep3B, IC₅₀ = 10, and PLC5, IC₅₀ = 19).
The product is subject to the following: Abcam Restricted Use Statement
Abcam SGI1776, 5MG
MW 405.4 Da, Purity >99%. Novel ATP competitive inhibitor of Pim1 with IC50 of 7 nM, 50- and 10-fold selective versus Pim2 and Pim3. Preliminary results from studies treating prostate cancer cells.
The product is subject to the following: Abcam Restricted Use Statement
Abcam CCT128930, 10MG
MW 341.8 Da, Purity =98%. Potent and selective AKT2 inhibitor (IC50= 6 nM) with selectivity greater than 28-fold and 20-fold over PKA kinase (IC50= 168 nM) and p70S6K (IC50= 120 nM), respectively.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Bafetinib (INNO-406).
Bafetinib (INNO-406).
The product is subject to the following: Abcam Restricted Use Statement
Abcam SB742457 (Intepirdine), 5-HT6 antagonist, 5MG
MW 353.4 Da. Potent (pKi = 9.63) and highly selective 5-HT6 antagonist. Greater thsan 100-fold selective against other receptors. Reverses learning impairment in animal models.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Prostaglandin A1, 1MG
MW 336.5 Da. Endogenous prostaglandin with diverse biological actions including anti-hypertensive, anti-inflammatory, anti-viral and anti-cancer properties.
The product is subject to the following: Abcam Restricted Use Statement
Abcam LM22A-4, neurotrophic BDNF mimetic, 50MG
MW 339.34 Da, Purity >98%. Small molecule BDNF mimetic displaying neurotrophic activity. Partial agonist at TrkB, activating TrkB signaling. Displaces BDNF (IC₅₀ = 47 nM) in binding assays. Prevents neuronal degeneration with equal efficacy to that of BDNF in in vitro models of neurodegenerative disease. Causes hippocampal and striatal TrkB activation in mice and improved motor learning after traumatic brain injury in rats, after in vivo administraton. Improves respiratory function in a mouse model of Rett syndrome.
The product is subject to the following: Abcam Restricted Use Statement